Transfer of Shares and Director/PDMR Shareholding

RNS Number : 8262U

Diaceutics PLC

08 April 2021

 

Diaceutics PLC

("Diaceutics" or the "Company")

Transfer of Shares and Director/PDMR/PCA Shareholding

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, has today been informed that Delia Keeling, wife of Peter Keeling, the Chief Executive Officer and a PCA, has made the following transfers, of a total of 250,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") for nil consideration to the following persons:

· 100,000 Ordinary Shares to Robyn Keeling, wife of Ryan Keeling, the Chief Innovation Officer, also a PCA;

· 50,000 Ordinary Shares to Philip White, the Chief Financial Officer; and

· 100,000 Ordinary Shares to certain family friends.

As a result of these transfers, the beneficial holdings of the following directors and their connected parties in the Ordinary Shares of the Company are as follows:

· Peter Keeling, 17,252,049 Ordinary Shares, representing 20.52 % of the Company's issued share capital;

· Ryan Keeling, 2,990,643 Ordinary Shares, representing 3.56 % of the Company's issued share capital; and

· Philip White, 1,956,389 Ordinary Shares, representing 2.33 % of the Company's issued share capital.

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Paul McManus		Mob: [phone]

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform.

About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Delia Keeling
2	Reason for notification
a.	Position/Status	PCA, wife of Peter Keeling
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Transfer of Shares to four individual persons
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Nil	100,000
			Nil	50,000
			Nil	50,000
			Nil	50,000
			Total	250,000
e.	Date of the transaction	6 April 2021
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Robyn Keeling
2	Reason for notification
a.	Position/Status	PCA, Wife of Ryan Keeling
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Receipt of shares from Delia Keeling
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Nil	100,000
e.	Date of the transaction	6 April 2021
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Philip White
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Receipt of shares from Delia Keeling
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			Nil	50,000
e.	Date of the transaction	6 April 2021
f.	Place of the transaction	Outside a trading venue

 

END

 

 

DSHSSMSAAEFSELL